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Epilepsy is a common, complex and often challenging neurological disorder to treat in the
dog, with 20–30% of dogs resistant to conventional medical therapies, and associated
with cognitive and behavioral comorbidities and early death. Behavioral interventions
are an emerging area of focus in the adjunctive treatment of drug-resistant human
epilepsy patients, with studies indicating positive effects of a variety of interventions
including relaxation-based techniques and behavioral therapy interventions. Behavioral
interventions have the potential not only to improve seizure control, but also improve
behavioral comorbidities and general quality of life in this hard to treat patient group.
Despite striking similarities between human and canine epilepsy patients, including the
recognition of co-morbid anxiety in epilepsy patients, behavioral interventions have yet
to be studied in dogs. This is compounded by several licensed psychopharmaceutical
agents for dogs being contra-indicated in epilepsy patients. We present evidence from
human studies of the efficacy of behavioral interventions to improve seizure control,
psychiatric comorbidities and quality of life, and propose that adapting such interventions
for canine patients may be a valuable addition to the epilepsy management toolkit. There
is a need for multi-center, double-blinded, placebo-controlled trials to confirm the effects
of behavioral interventions on seizure frequency in veterinary medicine. In the absence of
such evidence to date, the use of established behavioral medicine techniques to reduce
stress and improve the mental health of these often sensitive and challenging patients is
advocated, with a greater role for behaviorists in the management of epilepsy patients
alongside neurologists and general practitioners.
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CANINE EPILEPSY: CURRENT THERAPIES AND CHALLENGES
Epilepsy is the most common chronic neurological presentation in first opinion practice for
domestic dogs, with previous epidemiological studies estimating a prevalence of 0.6% of dogs
affected in the UK alone (1). Epilepsy is a major risk to the health and welfare in dogs, with dogs at
risk of developing behavioral changes such as anxiety and attention-deficit hyperactivity disorder
(ADHD)-like behavior, cognitive impairments, reduced quality of life (QoL) from anti-epileptic
drug (AED) side effects, complications of AED treatments and early death (2–7). Between 20 and
60% of dogs with IE die as a direct consequence of epilepsy (8). The condition is early onset, with
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most dogs experiencing their first seizure between 1 and 4 years of
age, and is lifelong (9), requiring chronic medication. Medication
with AEDs poses a fine balance between benefits and harms, with
potentially adverse welfare consequences due to unpleasant side
effects including excessive hunger, thirst, restlessness, lethargy,
and ataxia (4). Their impact upon QoLmay be considerable, with
AED side-effects being cited as an important consideration for
owners of epileptic dogs (4).
Despite advances in pharmacotherapy for canine idiopathic
epilepsy (IE), with an increasing number of AEDs available to
veterinarians managing these often challenging patients, a large
proportion of this patient population continue to experience
seizures while taking AEDs. At present, only a minority of
canine epilepsy patients achieve significant periods of seizure
freedom (10). Overall response rates (defined as >50% reduction
in seizure frequency) to the first, second and third AEDs
have been reported as 37.2, 10.7, and 6.1%, respectively (11);
and thus many dogs continue to seizure chronically despite
polytherapy. This parallels findings in human neurology, where
up to 30% of epilepsy patients continue to seizure despite
taking AEDs (12). Although AEDs remain the mainstay of
epilepsy treatment in dogs, seizure control is often incomplete
and their use is associated with a variety of quality of life
inhibiting side effects including sedation, ataxia, polyphagia (5).
Indeed, a recent meta-analysis of 90 canine epilepsy studies
identified adverse effects associated with all nine of the most
commonly used AEDs (13). The discovery of adjunctive therapies
that effectively reduce seizure frequency in canine epilepsy
patients, while avoiding additional side effects is of high priority.
Non-pharmacological seizure control strategies are becoming
increasingly common in both canine and human epilepsy,
including dietary interventions [e.g., the ketogenic diet; (14,
15) and the use of dietary supplements (16)], and implantable
neuromodulation devices [e.g., vagal nerve stimulators; (17,
18)]. Although non-pharmacological therapies including dietary
and neuromodulation interventions have been demonstrated to
improve seizure frequency in some patients, others still fail to
achieve a significant level of seizure control following these
adjunctive therapies (commonly considered a>50% reduction in
dogs), and thus the search for additional adjunctive therapies for
the epilepsy management tool-kit continues.
An emerging area in adjunctive therapies for drug-resistant
human epilepsy patients is behavioral and psychological
therapies. These interventions are based on accumulating
evidence from animal models and clinical studies that there is a
relationship between behavioral, physiological and psychological
states and the probability of seizure occurrence, with a
bidirectional relationship between seizures and psychological
states (19). Interventions that alter behavioral or psychological
states have been tested to determine whether they can reduce
the occurrence of seizures in people with epilepsy, with success
found with a variety of interventions. To date, this type of
intervention for drug-resistant canine epilepsy patients remains
entirely unexplored to the authors’ knowledge, but offer much
promise. There are striking similarities between canine and
human epilepsy patients, with shared characteristics including
spontaneous drug-resistance (20) and behavioral and cognitive
comorbidities (2, 6, 7, 21). Many of the same drug and non-
drug therapies (e.g., the MCT diet) have proven efficacious in
both species, and as such, exploring behavioral interventions
in dogs appears both logical and overdue. Potential benefits of
behavioral interventions include their relatively low cost, lack
of side effects and contra-indications with existing medications,
and their non-invasive nature (22). As recently highlighted by
Kanner (23), the treatment of epileptic seizure disorders is not
restricted to the achievement of seizure-freedom, but must also
include the management of co-morbid psychiatric and cognitive
comorbidities (23).With the increasing recognition of behavioral
and cognitive comorbidities in dogs with epilepsy (2, 6, 7, 21),
the potential for behavioral interventions improving both seizure
control and behavioral clinical outcomes warrants investigation
in this area in canine patients.
EVIDENCE FOR BEHAVIORAL
INTERVENTIONS FOR EPILEPSY
Behavioral treatments for epilepsy in humans have been
discussed since 1977 (24), but have not been subjected to
investigation in rigorous clinical trials until recently, with the
development of psychosocial treatment programs not keeping
pace with the development of medical treatments (25). Despite
this, behavioral techniques to control seizures have a long history
with a multitude of empirical studies published on a variety
of interventions. Many of these behavioral interventions target
stress. Stress is increasingly recognized to have a major role in
epilepsy, including: (i) acting as a risk factor for the development
of epilepsy, (ii) being a trigger for the occurrence of seizures
in some individuals with epilepsy, and (iii) exacerbating seizure
frequency, and/or being an important component of a prodrome
preceding a seizure in some individuals with epilepsy (26).
Recent research has demonstrated that epilepsy is associated
with elevated stress in both dogs with epilepsy and their owners
(27); however, measures to counteract stress have yet to be
explored in this population. Behavioral interventions to reduce
stress and improve emotional state for people with epilepsy
have included relaxation exercises including yoga and progressive
muscle relaxation, biofeedback and cognitive behavioral therapy,
which will now be briefly reviewed. Evidence is additionally
summarized in Table 1.
Relaxation-Based Techniques
Stress management techniques have been demonstrated to show
strong preliminary evidence in seizure reduction in people
with epilepsy. A well-studied technique is progressive muscle
relaxation (PMR) which involves tensing and releasing different
muscle groups in turn. In a recent multicenter randomized
controlled trial (RCT), n = 66 adults with refectory epilepsy
were randomized into one of two interventions; PMR with
diaphragmatic breathing or control focused-attention activity
with extremity movements. Participants underwent 12 weeks of
double-blind treatment, and seizure frequency during this period
was compared to the 8 week baseline phase before treatment
commenced. In both groups, seizure frequency was significantly
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reduced from baseline; however, there was no difference in the
efficacy of the two groups (26). PMR was more effective in
reducing self-reported stress than focused attention (26). Prior
to this RCT, several smaller studies demonstrated the promise
of this technique. In a small study of epilepsy patients (n = 8),
half underwent 3 weeks of PMR while half in the control arm
underwent 3 weeks of quiet sitting, followed by 3 weeks of PMR.
All subjects showed decreases in seizure frequency from baseline
to treatment and improvements in well-being (28). In a further
study of n = 18 adults with drug-resistant epilepsy, patients
were split into three groups: contingent relaxation, attention
control, and no-treatment (control) for 6 weeks. Patients in
the contingent relaxation group were instructed to apply PMR
techniques to situations or feelings associated with high risk
of seizure activity. Results indicated that seizure frequency
was significantly reduced in the PMR group (29). A further
study compared the 8 week baseline seizure frequency for 12
participants with three subsequent 8 week follow-up periods,
post PMR training. During the intervention period, PMR was
practiced twice a day. By the third follow-up time point, the
median seizure frequency for the group had decreased by 54%
(31). Finally, in a study of n = 24 adults with epilepsy, a seizure
frequency reduction of 29% was associated with six sessions of
progressive relaxation training (n = 13) compared with just 3%
in patients with six sessions of quiet sitting (n= 11) (30).
In addition to PMR, another relaxation-based technique, yoga,
has shown efficacy in seizure control for some patients with
epilepsy. Yoga is an ancient Indian philosophy of life aimed
at achieving the highest possible functional harmony between
body and mind, which involves control of posture, breathing
and meditation. Yoga may have an effect on the probability of
seizure occurrence due to its effect on brain wave activity and
arousal levels (39). It has been further suggested that yoga may
stimulate the vagus nerve which may in turn decrease seizure
frequency (40). Studies have demonstrated that certain types of
yoga increase central parasympathetic activity and sensory motor
rhythm and increase the sense of well-being (41, 42). In a study
by Sathyaprabha and colleagues, 10 weeks of daily 60-min yoga
practice (n = 18 epilepsy patients) was found to significantly
decrease seizure frequency and parasympathetic dysfunction,
compared to a group that practiced routine exercises involving
sitting quietly for 20min and simple physical exercises for 40min
who showed no reduction (n = 16) (32). In a further RCT by
Lundgren et al. (22), drug-resistant epilepsy patients treated with
either yoga (n = 8) or acceptance and commitment therapy
(a cognitive technique; n = 10) experienced reduced seizure
frequency and duration and increased quality of life compared
to baseline (22).
Finally, training patients to relax using biofeedback has shown
promise in controlling seizures. Biofeedback is a management
tool where the patient is provided with visual or audio feedback to
covert physiological responses occurring in their body, including
changes in heart rate, skin conductivity or brain activity (from
electroencephalography; EEG). Training may allow the patient
to learn to actively control these bodily responses and use this
biofeedback training as a countermeasure when they are aware a
seizure is about to start (33). Negative amplitude shifts of cortical
potential are related to seizure activity in epilepsy; regulation of
the cortical potential with biofeedback has been successfully used
to reduce the frequency of some patients’ seizures (43). Galvanic
Skin Response (GSR) is a sensitive measurement of autonomic
arousal and physiological state which reflects one’s behavior; a
high skin resistance state reflects a state of relaxation and a low
skin resistance state reflects a state of arousal. Nagai et al. found
that GSR biofeedback training reduced seizure frequency in the
biofeedback (n = 10) but not the sham control biofeedback (n
= 8) group, thus demonstrating the promise of this technique
(33). In addition, a meta-analysis of EEG biofeedback studies
for epilepsy management found a 74% reduction in weekly
seizures (44). This method is currently out of the scope of
potential treatment techniques for canine patients, however
if canine ambulatory EEG technology improves and becomes
more widespread in the future, this may be another method to
consider.
Behavioral Therapy Techniques
In addition to relaxation-based interventions, a variety of
behavioral therapy based techniques have been trialed in humans
with epilepsy, as techniques to improve both seizure control,
treat psychiatric co-morbidities and more improve QoL more
generally. In a crossover design study, Gillam compared the
effect of two psychological approaches: one treatment focused
on seizures, and involved training patients to identify factors
that might precipitate seizures, to learn how to avoid these
“triggers,” to try to interrupt seizures in the early stages of their
occurrence, or to practice relaxation and breathing exercises,
the other targeted psychological problems affecting the patients
such as phobias, mild depression, and family tensions (34). Both
techniques were effective in reducing psychological symptoms
and seizure frequency, with the author concluding that the
improved sense of self-control may have been more important
than whether the intervention was targeted at psychological
difficulties or seizures specifically. In a further study, Spector et al.
(35) employed a group intervention in adults with drug-resistant
epilepsy (n = 8). The intervention, based on a programme
developed by Andrews and Reiter, “Taking Control of Your
Epilepsy” (45) and recently updated in 2015 (46) involved a
variety of measures including support and dealing with stigma,
understanding epilepsy and antiepileptic drugs, identifying
auras, identifying and avoiding triggers for seizures, channeling
negative emotions into productive outlets, and dealing with stress
(35). Following treatment there was a significant reduction in
seizure frequency, which persisted at 8 week follow up (35).
Behavioral medicine in the form of cognitive behavioral
therapy (CBT) has further been explored as an intervention
for epilepsy, with mixed results to date. CBT emphasizes the
influence of thoughts and their content on emotional state and
treatment focuses on changing thought patterns and behavior.
In a study of n = 37 adults with epilepsy, patients were
assigned to either a 6 week CBT program or a control group.
Seizure frequency was significantly reduced in the CBT group
compared to the control (36). Conversely in earlier studies,
although beneficial effects upon general QoL were found, positive
effects on seizure frequency were not. A recent study assigned
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adults with epilepsy (n = 17) to either a treatment group (n
= 7) consisting of 8 weekly 2-h group CBT sessions, or to a
waitlist control group (n = 9). Although the treatment group
showed improvements in QoL [as measured by the QOLIE-
31 (47)], no significant reduction in seizure frequency was
found in the CBT group (37). Similar findings were reported
in an earlier study (38), where no evidence to support the
use of CBT for seizure reduction was found. In that study,
n = 27 adults with epilepsy were assigned to one of three
groups: CBT, supportive counseling (attention-placebo control)
and waiting list (no treatment control). No difference was found
in seizure frequency between the three groups; however, ratings
of psychological adjustment were found to improve for the two
therapy groups (38).
Treatment of Epilepsy Co-morbidities
As highlighted earlier, epilepsy treatment should not solely
focus on seizure control. Behavioral interventions may reap
benefits in addition to reduced seizure frequency. In a recent
Cochrane review of psychological and behavioral treatments
for health-related quality of life in epilepsy patients (rather
than seizure frequency as the primary outcome) (48), 24
randomized controlled trials (RCTs) were included, of which 11
were considered psychological interventions including cognitive,
behavioral and mindfulness-based interventions. The impact
of these interventions on QoL, as measured by a validated
scale [the QOLIE-31 (47)] was significant and exceeded the
threshold of minimally important change, indicating a clinically
meaningful post-intervention improvement of QoL (48). Overall
QoL, including mental health should be taken seriously in
addition to seizure frequency in epilepsy patients, with inter-
ictal anxiety and depression found to have greater adverse effects
on QoL than seizure frequency, severity or chronicity in people
with epilepsy (49). With anxiety found more commonly as
a comorbidity in drug-resistant dogs (2), finding appropriate
treatments to reduce the effects of behavioral comorbidities and
improve general QoL alongside improved seizure control should
be the goal of epilepsy treatment.
IS THERE A NEED FOR BEHAVIORAL
THERAPY IN CANINE EPILEPSY
PATIENTS?
In addition to seizure control, there is an emerging need for
therapies for co-morbid anxiety in dogs with epilepsy. Increases
in anxiety following the onset of epilepsy have been documented
in dogs with epilepsy (2); however, in a recent review on
psychopharmacological options for the treatment of anxiety in
dogs with IE, it was concluded that there is a scarcity of evidence
of the effects of standard anxiolytic therapies in the IE population,
with many drugs having pharmacokinetic interactions with
AEDs, or contraindicated in these patients (50). Furthermore,
patient response to anxiolytic medications may differ between
healthy brains and epileptic brains. Although seizure reducing
effects were documented in a recent study of imepitoin (an
anti-consultant and anxiolytic), no changes in anxiety behavior
were observed in dogs with IE (51), whereas positive effects on
anxiety have been documented in otherwise healthy dogs with
fear or anxiety problems (52). In addition to pharmaceutical
interventions, some owners are already employing dietary
therapies aimed at epilepsy and its comorbidities. In a recent
study, 1 in 10 owners of epileptic dogs that were using dietary
supplements reported that their aim was to improve behavioral
problems associated with epilepsy (16). The use of behavioral
therapy has been advocated in this population (50); however, its
efficacy has yet to be ascertained with controlled trials, or indeed
reported in case reports or series as yet.
POTENTIAL BEHAVIORAL
INTERVENTIONS FOR CANINE EPILEPSY
PATIENTS
Although some of the aforementioned behavioral interventions
for human epilepsy patients rely upon methods based upon
language or higher level cognitive processes, and may not be
readily adapted to canine patients, the principles of other effective
techniques may be used to design potential interventions. These
include:
“Trigger” Management: As employed in several human
behavioral intervention studies, the recognition, and subsequent
avoidance of seizure triggers (seizure precipitating factors) may
improve seizure control in epileptic patients (34, 35). Seizure
triggers have recently been documented in two studies of canine
epilepsy patients, with many of these precipitants psychological
(53, 54), including general stress, changes in routine, unfamiliar
places or people visiting. Developing methods to reliably identify
seizure triggers and to teach owners to recognize these stimuli
may allow for either their avoidance, or the use of behavioral
therapy to systematically desensitize dogs to these stimuli using
controlled exposure (where possible) under the guidance of a
clinical animal behaviorist. Although it may not be possible to
avoid all seizure triggers, some reduction in seizure frequency
may be achieved by manipulation of the environment (55). In
addition to canine patients diagnosed with idiopathic epilepsy,
dogs with reflex epilepsy (i.e., seizure activity triggered by
exposure to specific locations or situations) (56) are likely to
strongly benefit from this behavioral management strategy.
Stress Reduction Therapies: The use of behavioral therapy
principles to improve the mental health of dogs, including:
improved consistency of dog-owner interactions, cessation of
any punishment-based training or training devices [previously
shown to be used by owners of epileptic dogs (7)], and improved
predictability of the dog’s life with enhanced feelings of control,
may be a potential way to reduce overall stress and improve
seizure control (57–59). Indeed, a previous human behavioral
intervention study found no difference in seizure control
between treatment programmes focused on general psychological
problems vs. seizures themselves specifically, with the author
concluding that the improved sense of self-control induced by
either programme may have been more important than the
specific type of intervention. Development of general stress
reduction programmes for epilepsy patients has the potential
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to improve seizure control while also improving overall QoL of
these patients by improving mental health.
Specific Relaxation Based Activities: There is growing
evidence that dogs with epilepsy exhibit behavioral changes
preceding a seizure event, which may represent the “prodromal”
stage of the seizure cycle. In a study of n = 229 owners
of dogs with epilepsy, 65% reported that dogs showed pre-
seizure changes including included restlessness, clinginess and
fearfulness (54). As implemented in human studies [e.g., Dahl
et al. (29)], it is possible that applying acute relaxation based
interventions during this pre-seizure stage may be effective
in aborting impending seizure activity, if seizure generation
is influenced by stress levels and cortical excitability can be
dampened by relaxation based activities. At present, further
research is needed to confirm the presence of this phase of
the “seizure cycle” in dogs and whether this window of time
for intervention exists. Relaxation sessions, aimed at reducing
physiological arousal and thereby increasing the threshold for
response to sensory signals, are used as a foundation for
modifying context-specific behavior in many clinical behavior
cases (60, 61) and daily relaxation outside of the prodromal phase
may act as an anxiolytic if dogs are trained to effectively settle in
a low arousal, positively valenced state.
CONCLUSIONS
Studies of behavioral interventions as tools to improve seizure
control and QoL show great promise for human drug-resistant
epilepsy patients. Despite the limitations of some of the early
studies in this area, with small sample sizes commonplace, the
fact that significant reductions in seizure frequency were found
in such small samples provides compelling preliminary evidence
for the strength of these interventions.
With great similarities exhibited between drug resistant
human and canine epilepsy patients (62), trialing behavioral
methods for this challenging population is timely and urgently
needed. There are both challenges and opportunities in the use
of behavioral methods, with important lessons to be learned
from the past 40 years of human research in this field. Well-
designed and powered studies are needed to successfully address
whether behavioral treatments can increase seizure threshold and
improve seizure control in drug resistant epilepsy patients. In
both veterinary and human medicine there is a need for multi-
center, double-blind, placebo-controlled trials to confirm the
effects of behavioral interventions on seizure frequency.
In the absence of such evidence to date, the use of
established behavioral medicine techniques to reduce stress and
improve mental health of these often sensitive and challenging
patients is advocated. Basic principles for all patients include
the cessation of all punishment-based training techniques
employed by owners. Greater education for owners on both
overt and subtle signs of stress in their dog is essential for
all behavioral interventions, and vets should either advise
clients individually of these signs, or be able to direct owners
to appropriate, evidence-based resources on this topic. We
advocate a greater role for veterinary behaviorists in the
management of epilepsy patients alongside neurologists and
general practitioners, not only for epileptic patients with overt
behavioral problems that owners actively seek treatment for
(e.g., noise phobias), but also for expert opinion on a dog’s
behavioral husbandry and lifestyle with the aim of generally
improving of the mental health and QoL of these sensitive
patients.
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